Dyslipidemias encompass abnormalities in the concentration, distribution, and metabolism of plasma lipoproteins. The term does not simply mean excess total cholesterol: it includes increased LDL, triglyceride-rich lipoproteins and their remnants, combinations of these abnormalities, and genetically determined conditions such as elevated lipoprotein(a). Clinical significance depends on the particles involved, their persistence in the circulation, the duration of exposure, and the cardiovascular and metabolic context. Two people with the same total cholesterol may therefore have markedly different pathogenic mechanisms, prognoses, and treatment needs.
This family of conditions connects the physiology of lipid transport with two major clinical problems. The first is atherosclerotic disease, promoted by exposure to apolipoprotein B-containing particles that can be retained in the arterial wall. The second is acute pancreatitis associated with severe forms of hypertriglyceridemia, especially when chylomicrons accumulate. Vascular risk often develops over decades; pancreatic risk can become a priority within a short time. Recognizing which predominates is part of the initial assessment, not a distinction to postpone until medication is chosen.
Cholesterol and triglycerides perform essential biological functions but are not freely soluble in plasma. They are transported by particles composed of lipids and apolipoproteins, with different compositions and destinations. Chylomicrons primarily distribute dietary lipids; VLDL transport triglycerides produced or processed by the liver; their progressive metabolism generates remnants and LDL. HDL participate in cholesterol exchange and transport through a heterogeneous population of particles. A lipid abnormality may result from excessive production, insufficient clearance, or changes in the steps connecting these pathways.
The distinction between primary and secondary forms is useful but does not capture the full clinical complexity. In primary disorders, genetic determinants predominate, sometimes attributable to a single gene but more often to numerous variants with small effects. Secondary forms involve conditions such as hypothyroidism, uncontrolled diabetes, kidney disease, cholestasis, excessive alcohol intake, or medications. Many patients have both components: a predisposition that remains relatively mild may become evident after weight gain, the development of insulin resistance, or the introduction of a treatment that interferes with lipid metabolism.
Dietary factors contribute through different mechanisms. High saturated fat intake can raise LDL; excess energy intake, simple sugars, and alcohol particularly promote hepatic production of triglyceride-rich lipoproteins. Visceral adiposity alters fatty acid delivery to the liver and is associated with a combination of elevated triglycerides, reduced HDL-C, and LDL particles that are relatively cholesterol-depleted. However, not all dyslipidemias result from diet, and normal body weight does not rule out an important inherited disorder.
The term dyslipidemia describes a cross-cutting clinical problem: identifying an abnormal profile, confirming it, investigating its causes, and determining which consequences to prevent. The lipid phenotype provides a starting point, while etiological diagnosis requires integration of trends over time, family history, comorbidities, and any specialist investigations. The name of an individual abnormality cannot replace this reconstruction.
In atherogenic hypercholesterolemia, increased LDL-carried cholesterol predominates. Its association with vascular events depends on cumulative exposure: a moderately elevated concentration over many years may be clinically significant even when short-term risk appears low. Familial hypercholesterolemia is a specific form in which an impaired LDL clearance pathway causes an increased LDL burden from early life. Identifying it also involves family members and changes how early prevention should begin.
Hypertriglyceridemia encompasses presentations ranging from moderately elevated VLDL to persistent chylomicronemia. It is not a homogeneous condition: accumulation of cholesterol-rich remnant particles contributes to atherosclerotic risk, whereas large chylomicrons are particularly important for pancreatic risk. The magnitude and variability of the increase help distinguish multifactorial forms from rare, profound disorders of intravascular lipolysis.
Simultaneous elevation of cholesterol and triglycerides characterizes mixed dyslipidemia. This pattern may reflect overproduction of apoB-containing particles, insulin resistance, secondary causes, or defects in remnant metabolism. The amount of cholesterol carried by each particle can vary widely: LDL-C alone may therefore underestimate atherogenic particle burden, making non-HDL cholesterol and, when indicated, apoB particularly useful.
Elevated lipoprotein(a), by contrast, is predominantly genetically determined and may occur alongside a largely unremarkable conventional lipid profile. It provides additional information on atherosclerotic risk and calcific aortic stenosis that is not fully captured by LDL cholesterol. Measuring Lp(a) is not the same as genetic panel testing and does not necessarily require fasting; interpretation must respect the measurement units and analytical method, without universal conversion between mass and molar concentrations.
Atherogenic particles share the presence of apolipoprotein B but differ in size, lipid content, and metabolic behavior. LDL and sufficiently small remnants can cross the endothelium and interact with the intimal matrix. Their retention triggers cholesterol accumulation and cellular responses that sustain plaque growth. Plasma concentration does not directly measure the arterial damage already present: it describes an exposure that must be considered alongside its duration and other factors promoting disease.
LDL cholesterol is the principal therapeutic target because of the strength of causal evidence and intervention trials. Non-HDL cholesterol summarizes the cholesterol carried by non-HDL particles, whereas apoB provides an estimate of their number. These markers are correlated but are not interchangeable in every patient. Discordance becomes particularly significant when particles carry less cholesterol than usual, as may occur in diabetes and hypertriglyceridemia.
Low HDL-C may signal an unfavorable metabolic milieu but does not automatically identify a drug target to raise. HDL cholesterol concentration does not capture all the functions of these particles; raising it with medication does not guarantee vascular benefit. Treatment therefore focuses on modifiable exposures with proven clinical benefit, avoiding interpretation of every out-of-range result as an independent target.
Most lipid abnormalities remain asymptomatic. The absence of symptoms does not reduce the significance of persistent atherogenic exposure; instead, it makes identification before an event essential. History-taking should reconstruct previous values, treatments already taken, personal and family vascular events, episodes of pancreatitis, eating habits, alcohol consumption, and medications. Signs such as tendon xanthomas, eruptive xanthomas, or premature corneal arcus suggest particular mechanisms, but their absence does not rule out clinically important dyslipidemia.
An initial lipid profile includes total cholesterol, HDL-C, triglycerides, and LDL-C measured or estimated by an appropriate method. Nonfasting samples are acceptable for screening in many settings; high triglyceride values, suspected chylomicronemia, or the need for metabolic characterization may require a fasting sample. Unexpected results should be confirmed under clinically stable conditions, accounting for biological variability and the effects of acute illness.
Investigation of secondary causes is guided by the clinical picture: thyroid function, blood glucose or glycated hemoglobin, kidney function and proteinuria, and liver and cholestasis markers can clarify the origin of the abnormality. There is no need to order every available test indiscriminately. Genetic tests, specialized lipoprotein analyses, and investigations for rare diseases become valuable when a precise clinical suspicion makes the result interpretable and useful for the patient or family.
Choosing treatment also requires an assessment of cardiovascular risk. Already documented atherosclerotic disease, marked hypercholesterolemia, or certain renal and metabolic conditions cannot be mechanically reduced to a risk score intended for apparently healthy people. Imaging for subclinical disease is selective and useful when it may change an uncertain decision; it is unnecessary to confirm a simple biochemical finding and must not delay treatment that is already clearly indicated.
Treatment integrates correction of the cause, lifestyle, and pharmacological therapy proportionate to risk. Diet emphasizes fat quality, fiber, and appropriate energy intake; reducing simple sugars and alcohol is particularly important in hypertriglyceridemia. Physical activity and weight management improve the metabolic context without automatically replacing medication in genetic forms or high-risk patients. Interventions must be sustainable and adapted to the clinical situation rather than reduced to generic food prohibitions.
To lower LDL, statins are the initial standard for most patients requiring medication. Ezetimibe, PCSK9 monoclonal antibodies, bempedoic acid, and inclisiran act at different points and allow combined or alternative strategies according to indication, tolerability, and the reduction required. Selection considers both the effect on the lipid parameter and evidence for clinical outcomes: studies of statins, ezetimibe, anti-PCSK9 antibodies, and bempedoic acid should not be confused with trials whose primary objective was solely LDL-C reduction.
In patients with very high triglycerides, preventing chylomicronemia and pancreatitis may require more stringent fat restriction than the diet usually recommended for hypercholesterolemia, alcohol abstinence, prompt diabetes control, and specific therapies. With moderate elevations, however, cardiovascular prevention remains focused on reducing the overall atherogenic burden. The benefit of icosapent ethyl in selected populations cannot automatically be extrapolated to any omega-3 supplement or every triglyceride-lowering drug.
Monitoring assesses response, adherence, and safety, as well as the persistence of modifiable causes. A smaller-than-expected response calls for checking actual medication use, interactions, clinical changes, and result reliability before declaring a drug class ineffective. Similarly, a symptom arising during treatment must be evaluated systematically, neither automatically attributed to medication nor ignored. Continuity of care is crucial because a favorable value achieved on treatment generally reflects its effect, not the disappearance of the underlying predisposition.
Prognosis depends on the duration of exposure, particle types, presence of atherosclerosis, and interactions with blood pressure, smoking, diabetes, and kidney disease. Preventive benefit is greater with higher baseline risk and when effective reduction in exposure is maintained for longer. For young people with inherited disorders, assessment must look beyond the 10-year horizon alone; for frail older adults, it must incorporate life expectancy, comorbidities, and individual preferences.
The principal vascular complications include myocardial infarction, ischemic stroke, and peripheral artery disease, potentially leading to heart failure, disability, and loss of independence. Pancreatitis is a distinct complication of severe hypertriglyceridemia; calcific aortic stenosis has a specific association with Lp(a). These outcomes are not inevitable: etiological identification, early intervention, and sustained control substantially modify the clinical course, although they do not eliminate every determinant of risk.
Informational notice: the information contained on this page is provided solely for informational and educational purposes and does not replace the advice, diagnosis or treatment provided by a physician. If needed, always consult a qualified healthcare professional.
Artificial intelligence transparency: this page was created with the support of artificial intelligence tools, used to assist in the production and processing of its content.